Article Text

Download PDFPDF
Association of plasminogen activator inhibitor-type 1 (−675 4G) polymorphism with pre-eclampsia: systematic review
  1. J Morgan,
  2. L Young,
  3. W McGuire
  1. Centre for Reviews and Dissemination, Hull York Medical School, York, UK


Background Plasma levels of plasminogen activator inhibitor-type 1 (PAI-1) are higher in women with severe pre-eclampsia/eclampsia (PE/E) than in gestation-matched non-hypertensive pregnant women. The PAI-1 (−675 4G) promoter polymorphism increases transcriptional activity and is a putative risk factor for PE/E. The aim of this study was synthesise the available evidence for the association of the PAI-1 (−675 4G) polymorphism with PE/E.

Methods Systematic review and random effects meta-analysis of genetic association studies using HuGE review methods.

Results 11 case-control studies in which a total of 1331 women with PE/E and 1536 controls participated were identified. The studies were generally small but of reasonable methodological quality. Random effects meta-analysis found a significant association: pooled odds ratio 1.36 (95% CI 1.13 to 1.63). (Figure 1). There was not any statistical evidence of heterogeneity (I2=0%).

Abstract PMM.12 Figure 1

Forest plot of odds of PAI-1 (−675 4G/4G) in PE/E versus controls.

Conclusions This meta-analysis suggests that women with PE/E have a 36% increased odds of possession of the PAI-1 (−675 4G/4G) polymorphism. These findings if confirmed in a larger genetic association studies may have implications for both clinical care (targeted surveillance or prophylaxis) and future research to define the pathogenesis of this condition.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.